Ellen Stelloo

4.2k total citations · 2 hit papers
32 papers, 2.7k citations indexed

About

Ellen Stelloo is a scholar working on Obstetrics and Gynecology, Reproductive Medicine and Cancer Research. According to data from OpenAlex, Ellen Stelloo has authored 32 papers receiving a total of 2.7k indexed citations (citations by other indexed papers that have themselves been cited), including 18 papers in Obstetrics and Gynecology, 15 papers in Reproductive Medicine and 13 papers in Cancer Research. Recurrent topics in Ellen Stelloo's work include Endometrial and Cervical Cancer Treatments (18 papers), Ovarian cancer diagnosis and treatment (14 papers) and Cancer Genomics and Diagnostics (9 papers). Ellen Stelloo is often cited by papers focused on Endometrial and Cervical Cancer Treatments (18 papers), Ovarian cancer diagnosis and treatment (14 papers) and Cancer Genomics and Diagnostics (9 papers). Ellen Stelloo collaborates with scholars based in Netherlands, United Kingdom and Australia. Ellen Stelloo's co-authors include Tjalling Bosse, Carien L. Creutzberg, Vincent T.H.B.M. Smit, Remi A. Nout, Hans W. Nijman, Elisabeth M. Osse, Jan J. Jobsen, David N. Church, Ludy Lutgens and Elzbieta M. van der Steen‐Banasik and has published in prestigious journals such as Molecular Cell, PLoS ONE and JNCI Journal of the National Cancer Institute.

In The Last Decade

Ellen Stelloo

30 papers receiving 2.6k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Improved Risk Assessment by Integrating Molecular and Clinicopathological Factors in Early-stage Endometrial Cancer—Combined Analysis of the PORTEC Cohorts

2016 569 citations Ellen Stelloo, Remi A. Nout et al. Clinical Cancer Research profile →
Refining prognosis and identifying targetable pathways for high-risk endometrial cancer; a TransPORTEC initiative

2015 341 citations Ellen Stelloo, Tjalling Bosse et al. Modern Pathology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Ellen Stelloo Netherlands	20	1.7k	1.2k	769	666	653	32	2.7k
Niki Boyd Canada	10	1.2k 0.7×	1.3k 1.1×	615 0.8×	554 0.8×	466 0.7×	13	2.6k
Nataliya Melnyk Canada	15	738 0.4×	755 0.6×	523 0.7×	422 0.6×	345 0.5×	18	2.0k
Janine Senz Canada	31	1.9k 1.2×	2.0k 1.7×	1.2k 1.5×	706 1.1×	932 1.4×	66	4.7k
Jennifer L. Santos Canada	13	558 0.3×	1.3k 1.0×	527 0.7×	416 0.6×	180 0.3×	21	2.0k
Ruth Perets Israel	18	394 0.2×	613 0.5×	493 0.6×	1.3k 1.9×	242 0.4×	61	2.7k
Christian Kurzeder Germany	25	494 0.3×	1.0k 0.8×	290 0.4×	709 1.1×	203 0.3×	88	2.0k
Kathy Han Canada	22	742 0.4×	268 0.2×	343 0.4×	865 1.3×	164 0.3×	102	2.7k
Elisabeth Wik Norway	23	523 0.3×	378 0.3×	382 0.5×	401 0.6×	140 0.2×	60	1.5k
Sharad Ghamande United States	22	333 0.2×	476 0.4×	216 0.3×	770 1.2×	185 0.3×	114	1.7k
Dominique Berton-Rigaud France	18	405 0.2×	655 0.5×	277 0.4×	1.0k 1.5×	234 0.4×	73	1.8k

Countries citing papers authored by Ellen Stelloo

Since Specialization

Citations

This map shows the geographic impact of Ellen Stelloo's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ellen Stelloo with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ellen Stelloo more than expected).

Fields of papers citing papers by Ellen Stelloo

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ellen Stelloo. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ellen Stelloo. The network helps show where Ellen Stelloo may publish in the future.

Co-authorship network of co-authors of Ellen Stelloo

This figure shows the co-authorship network connecting the top 25 collaborators of Ellen Stelloo. A scholar is included among the top collaborators of Ellen Stelloo based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ellen Stelloo. Ellen Stelloo is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Es, Robert M. van, Holger Rehmann, Jasper J. Anink, et al.. (2024). mTORC1 restricts TFE3 activity by auto-regulating its presence on lysosomes. Molecular Cell. 84(22). 4368–4384.e6. 5 indexed citations

Feitsma, Harma, Ellen Stelloo, Joost F. Swennenhuis, et al.. (2024). Proximity ligation‐based sequencing for the identification of human papillomavirus genomic integration sites in formalin‐fixed paraffin embedded oropharyngeal squamous cell carcinomas. Journal of Medical Virology. 96(8).

Stelloo, Ellen, Ruud W. J. Meijers, Joost F. Swennenhuis, et al.. (2023). Formalin-Fixed, Paraffin-Embedded–Targeted Locus Capture. Journal of Molecular Diagnostics. 25(10). 758–770. 3 indexed citations

Stelloo, Ellen, Miangela M. Laclé, Joost F. Swennenhuis, et al.. (2023). Comparison of NTRK fusion detection methods in microsatellite-instability-high metastatic colorectal cancer. Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin. 482(6). 983–992. 8 indexed citations

Zogchel, Lieke M. J. van, Ellen Stelloo, Joost F. Swennenhuis, et al.. (2023). Targeted locus amplification to develop robust patient-specific assays for liquid biopsies in pediatric solid tumors. Frontiers in Oncology. 13. 1124737–1124737. 2 indexed citations

Horeweg, Nanda, Remi A. Nout, Ellen Stelloo, et al.. (2022). 2022-RA-450-ESGO Benefit of adjuvant radiotherapy depends on molecular class of early-stage endometrial cancer. International Journal of Gynecological Cancer. 32. A95–A96. 1 indexed citations

Horeweg, Nanda, Marco de Bruyn, Remi A. Nout, et al.. (2020). Prognostic Integrated Image-Based Immune and Molecular Profiling in Early-Stage Endometrial Cancer. Cancer Immunology Research. 8(12). 1508–1519. 42 indexed citations

Witte, Chris J. de, Jose Espejo Valle-Inclán, Nizar Hami, et al.. (2020). Patient-Derived Ovarian Cancer Organoids Mimic Clinical Response and Exhibit Heterogeneous Inter- and Intrapatient Drug Responses. Cell Reports. 31(11). 107762–107762. 203 indexed citations

Wortman, Bastiaan G., Carien L. Creutzberg, Hein Putter, et al.. (2018). Ten-year results of the PORTEC-2 trial for high-intermediate risk endometrial carcinoma: improving patient selection for adjuvant therapy. British Journal of Cancer. 119(9). 1067–1074. 163 indexed citations

10.

Depreeuw, Jeroen, Ellen Stelloo, Elisabeth M. Osse, et al.. (2017). Amplification of 1q32.1 Refines the Molecular Classification of Endometrial Carcinoma. Clinical Cancer Research. 23(23). 7232–7241. 35 indexed citations

11.

Stelloo, Ellen, Remi A. Nout, Elisabeth M. Osse, et al.. (2016). Improved Risk Assessment by Integrating Molecular and Clinicopathological Factors in Early-stage Endometrial Cancer—Combined Analysis of the PORTEC Cohorts. Clinical Cancer Research. 22(16). 4215–4224. 569 indexed citations breakdown →

12.

Gool, Inge C. van, Ellen Stelloo, Remi A. Nout, et al.. (2016). Prognostic significance of L1CAM expression and its association with mutant p53 expression in high-risk endometrial cancer. Modern Pathology. 29(2). 174–181. 66 indexed citations

13.

Stelloo, Ellen, Anna M. Jansen, Elisabeth M. Osse, et al.. (2016). Practical guidance for mismatch repair-deficiency testing in endometrial cancer. Annals of Oncology. 28(1). 96–102. 226 indexed citations

14.

Gool, Inge C. van, Florine A. Eggink, Luke Freeman-Mills, et al.. (2015). POLE Proofreading Mutations Elicit an Antitumor Immune Response in Endometrial Cancer. Clinical Cancer Research. 21(14). 3347–3355. 231 indexed citations

15.

Gool, Inge C. van, Ellen Stelloo, Remi A. Nout, et al.. (2015). PROGNOSTIC VALUE OF L1CAM EXPRESSION AND ITS ASSOCIATION WITH MUTANT P53 EXPRESSION IN HIGH-RISK ENDOMETRIAL CANCER PATIENTS: A TRANSPORTEC STUDY. International Journal of Gynecological Cancer. 25. 258–259. 1 indexed citations

16.

Church, Dawn R., Ellen Stelloo, Nadejda Valtcheva, et al.. (2014). PROGNOSTIC SIGNIFICANCE OF POLE EXONUCLEASE DOMAIN MUTATION IN EARLY STAGE ENDOMETRIAL CANCER. Data Archiving and Networked Services (DANS).

17.

Stelloo, Ellen, Remi A. Nout, Natalja T. ter Haar, et al.. (2014). High concordance of molecular tumor alterations between pre-operative curettage and hysterectomy specimens in patients with endometrial carcinoma. Gynecologic Oncology. 133(2). 197–204. 72 indexed citations

18.

Stelloo, Ellen, Evangelos Pazarentzos, Scott Harding, et al.. (2014). The anticancer gene ORCTL3 targets stearoyl-CoA desaturase-1 for tumour-specific apoptosis. Oncogene. 34(13). 1718–1728. 11 indexed citations

19.

Church, David N., Ellen Stelloo, Remi A. Nout, et al.. (2014). Prognostic Significance of POLE Proofreading Mutations in Endometrial Cancer. JNCI Journal of the National Cancer Institute. 107(1). 402–402. 241 indexed citations

20.

Spaans, Vivian M., Ellen Stelloo, Dennis Kremer, et al.. (2014). Designing a High-Throughput Somatic Mutation Profiling Panel Specifically for Gynaecological Cancers. PLoS ONE. 9(3). e93451–e93451. 38 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact